These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 8573424)

  • 1. Therapeutic strategy in Paget's disease of bone.
    Meunier PJ; Vignot E
    Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paget's disease and its therapeutic management].
    Orcel P; Rousière M
    Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
    Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
    Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term therapy of Paget's disease of bone with EHDP.
    Siris ES; Canfield RE; Jacobs TP; Baquiran DC
    Arthritis Rheum; 1980 Oct; 23(10):1177-84. PubMed ID: 6775644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ; Gunasekera RD
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
    Yates AJ; Percival RC; Gray RE; Atkins RM; Urwin GH; Hamdy NA; Preston CJ; Beneton MN; Russell RG; Kanis JA
    Lancet; 1985 Jun; 1(8444):1474-7. PubMed ID: 2861411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
    Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
    Bone; 1994; 15(3):261-7. PubMed ID: 8068446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.